IMR Press / FBE / Volume 6 / Issue 1 / DOI: 10.2741/E688

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia
Show Less
1 Department of Leukemia, MD Anderson Cancer Center, Houston, TX, 77030, USA

*Author to whom correspondence should be addressed.

Academic Editor: Arthur E. Frankel

Front. Biosci. (Elite Ed) 2014, 6(1), 40–45; https://doi.org/10.2741/E688
Published: 1 January 2014
(This article belongs to the Special Issue Clinical antibody drug conjugates)
Abstract

Antibody-drug conjugates (ADCs) represent a major advance in the treatment of acute lymphoblastic leukemia (ALL). CD22 expression, seen in majority of patients with B-lineage ALL, is an ideal target for ADCs. Inotuzumab ozogamicin is an ADC comprised of a humanized IgG4 monoclonal antibody covalently linked to calecheamicin. Inotuzumab ozogamicin has shown promising single-agent activity in patients with ALL and in CD22 positive non-Hodgkin lymphoma. Studies exploring the combination of inotuzumab ozogamicin with chemotherapy are ongoing.

Keywords
Inotuzumab ozogamicin
Acute lymphoblastic leukemia
CD22
Immunoconjugate
Review
Share
Back to top